BMEA Latest Press Releases

-- October 13, 2026 --

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist Globe Newswire 4:08 PM

-- October 12, 2026 --

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist Globe Newswire 4:30 PM

-- September 23, 2026 --

Biomea Fusion Announces Termination of Proposed Public Offering of Securities Globe Newswire 7:03 AM

-- September 22, 2026 --

Biomea Fusion Announces Proposed Public Offering of Securities Globe Newswire 4:05 PM

-- September 3, 2026 --

Biomea Fusion to Participate in Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 24, 2026 --

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes Globe Newswire 7:00 AM

-- August 13, 2026 --

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity Globe Newswire 7:00 AM

-- August 5, 2026 --

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights Globe Newswire 4:05 PM

-- June 5, 2026 --

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study Globe Newswire 7:32 PM

-- June 3, 2026 --

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes